| Mar 5, 2026 | NexCure | $19.0M Series A | RA Capital Management | Cencora Ventures, Oncology Ventures |
| Mar 3, 2026 | Poplar Therapeutics | $45.0M Series A Extension | DAN Lyons | ArrowMark Partners, SR ONE, Vida Ventures |
| Feb 10, 2026 | ILiAD Biotechnologies | $115.0M Series D | RA Capital Management | AI Life Sciences Investments LLC, BNP Paribas Asset Management, Janus Henderson Investors, BNP Capital |
| Feb 10, 2026 | ILiAD Biotechnologies | $115.0M Series B | RA Capital Management | AI Life Sciences, BNP Capital, Janus Henderson Investors |
| Feb 5, 2026 | Angitia Biopharmaceuticals | $130.0M Series D | Frazier Life Sciences, Venrock | 3H Health Investment, Ascenta Capital, Bain Capital Life Sciences, BlackRock, BVF Partners, Elikon Venture, Hillhouse Capital Group, Janus Henderson Investors, Legend Capital, Logos Capital, Morningside, OrbiMed, TF Capital, Yonghua Capital |
| Jan 26, 2026 | Jixing Pharmaceuticals | $287.0M Series D | — | Adage Capital Management, HBM Healthcare Investments, Hengdian Group Capital, Invus, Roderick Wong, Silver ARC Private Capital, SR ONE, SymBiosis, TCGX |
| Jan 9, 2026 | Diagonal Therapeutics | $125.0M Series B | Janus Henderson Investors, Paulina Hill | Atlas Venture, Balyasny Asset Management, Biovision Ventures, BVF Partners, Checkpoint Capital, Deep Track Capital, EcoR1 Capital, Frazier Life Sciences, Lightspeed Venture Partners, Logos Capital, RV Invest, Velosity Capital, Viking Global Investors |
| Jan 8, 2026 | Century Therapeutics | $135.0M Other Equity | TCGX | Commodore Capital, Deep Track Capital, JDRF T1D Fund, RTW Investments, Venrock |
| Dec 12, 2025 | Sidera Bio | $110.0M Series A | — | Forbion, Novo Holdings |
| Dec 3, 2025 | Triana Biomedicines | $120.0M Series B | Lorence KIM, Andrew Hedin | Atlas Venture, Finchley Healthcare Ventures, Invus, Lightspeed Venture Partners, Regeneron Ventures, Surveyor Capital, YK Bioventures |
| Oct 1, 2025 | Hemab | $160.0M Series C | Soffinova Partners | Access Biotechnology, Amzak Health Investors, HealthCap, Avoro Capital Advisors, Deep Track Capital, Invus, MAJ Invest, Novo Holdings, Rock Springs Capital |
| Oct 1, 2025 | VitriVax | $17.0M Series B | Adjuvant Capital, RA Capital Management | Charles Petty |
| Sep 1, 2025 | Alchemab Therapeutics | $32.0M Series A | — | SV Health Investors, DCVC BIO, Mike Hutton, Lightstone Ventures, ONO Venture Investment, Kate Bingham |
| Aug 1, 2025 | Gameto | $44.0M Series C | Overwater Ventures | ARCH Venture Partners, Atomic, Bascom Ventures, Coatue, Future Ventures, Insight Partners, Khosla Ventures, NFX, TitletownTech, TWO Sigma Ventures, Anne Wojcicki, Arcadia Investments, Bold Capital Partners, Ingeborg Investments, Pagsgroup, Pontiva Healthcare Partners, Portfolia |
| Aug 1, 2025 | Reframe Systems | $20.0M Series A | VoLo Earth Ventures, Charly Mwangi | Cubit Capital, MassMutual, Nor'easter Ventures, Saga |
| Jun 12, 2025 | Commons Clinic | $26.0M Series B | RA Capital Management | Courtside Ventures, John Loser, SteelSky Ventures, Time BioVentures |
| Jun 1, 2025 | Spyglass Pharma | $75.0M Series D | Jake Merrill | Action Potential Venture Capital, Energy Impact Partners, JAY, Queensbridge Venture Partners, Seventure Partners, MO EL Bibany, TIM Ferriss, NEW Enterprise Associates, Samsara BioCapital, Vensana Capital, Vertex Ventures HC |
| May 1, 2025 | CellCentric | $120.0M Series C | Forbion, RA Capital Management | ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, HealthCap, INKEF Capital, Pfizer Venture Investments, Pontifax Venture Capital, SR ONE, Bill Gates, American Cancer Society, Avego Bioscience Capital, BrightEdge |
| Mar 1, 2025 | Vivace Therapeutics | $35.0M Series D | RA Capital Management | Canaan Partners |
| Feb 1, 2025 | Bambusa Therapeutics | $90.0M Series A | RA Capital Management | Arix Bioscience, Pivotal BioVenture Partners |
| Oct 1, 2024 | Evommune | $120.0M Series C | RA Capital Management, Sectoral Asset Management | Andera Partners, Arix Bioscience, Pivotal BioVenture Partners, Ysios Capital |
| Oct 1, 2024 | Be Biopharma | $82.0M Series U | — | ARCH Venture Partners, Atlas Venture, Biomatics Capital Partners, Leaps BY Bayer, LUX Capital, The Column Group, Isaac Ciechanover, Alta Partners, Bristol Myers Squibb, Longwood Fund, Takeda Ventures |
| Sep 4, 2024 | Vesta Healthcare | $65.0M Series C | RA Capital Management | — |
| Sep 1, 2024 | Superluminal Medicines | $120.0M Series A | RA Capital Management | AIR Street Capital, Humboldt Fund, Insight Partners, Spark Capital, Tencent Holdings, Jeremy YAP |
| Sep 1, 2024 | Aktis Oncology | $180.0M Series B | Janus Henderson Investors, RA Capital Management, RTW Investments | 5AM Ventures, Access Biotechnology, MPM Capital, Pontifax Venture Capital |
